Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis

Cancer Research

Volumn 58, Issue 8, 1998, Pages 1741-1749

  Ungefroren, Hendrik ^a   Voss, Martina ^a   Jansen, Martina ^a   Roeder, Christian ^a   Henne Bruns, Doris ^a   Kremer, Bernd ^a   Kalthoff, Holger ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; LIGAND; MESSENGER RNA;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION;

ADENOCARCINOMA; ANTIBODIES; ANTIGENS, CD95; APOPTOSIS; CARRIER PROTEINS; CELL MEMBRANE; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; CYTOPLASM; FAS LIGAND PROTEIN; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; JURKAT CELLS; MEMBRANE GLYCOPROTEINS; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; PROTEIN-TYROSINE-PHOSPHATASE; RECOMBINANT PROTEINS; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0032522848     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Cordon-Cardo, C., Fuks, Z., Drobnjak, M., Moreno, C., Eisenbach, L., and Feldman, M. Expression of HLA-A, B, C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res., 57: 6372-6380, 1991.
2. Restifo, N. P., Esquivel, F., Kawakami, Y., Yewdell, J. W., Mule, J. J., Rosenberg, S. A., and Bennink, J. R. Identification of human cancers deficient in antigen processing. J. Exp. Med., 177: 265-272, 1993.
3. Chen, L., Ashe, S., Brady, W. A., Hellström, I., Hellström, K. E., Ledbetter, J. A., McGowan, P., and Linsley, P. S. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTL-4. Cell, 71: 1093-1102, 1992.
4. Townsend, S., and Allison, J. P. Tumor rejection after direct stimulation of CD8+ T cells by B7-transfected melanoma cells. Science (Washington DC), 259: 368-370, 1993.
5. Mizoguchi, H., O'Shea, J. J., Longo, D. L., Loeffler, C. M., McVicar, D. W., and Ochoa, A. C. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science (Washington DC), 258: 1795-1798, 1992.
6. Nakagomi, H., Petersson, M., Magnusson, I., Juhlin C., Matsuda, M., Mellstedt, H., Taupin, J-L., Vivier, E., Anderson, P., and Kiessling, R. Decreased expression of the signal-transducing ζ chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res., 53: 5610-5612, 1993.
7. Finke, J. H., Zea, A. H., Stanley, J., Longo, D. L., Mizoguchi, H., Tubbs, R. R., Wiltrout, R. H., O'Shea, J. J., Kudoh, S., Klein, E., Bukowski, R. M., and Ochoa, A. C. Loss of T-cell receptor ζ chain and p56lck in T-cells infiltrating human renal cell carcinomas. Cancer Res., 53: 5613-5616, 1993.
8. Sulitzeanu, D. Immunosuppressive factors in human cancer. Adv. Cancer Res., 60: 247-271, 1993.
9. Nagata, S., and Golstein, P. The Fas death factor. Science (Washington DC), 267: 1449-1456, 1995.
10. Singer, G. G., and Abbas, A. K. The Fas antigen is involved in peripheral but not thymic deletion of T-lymphocytes in T cell receptor transgenic mice. Immunity, 1: 365-371, 1994.
11. 2+-independent T cell-mediated cytotoxicity. J. Exp. Med., 177: 195-200, 1993.
12. Saas, P., Walker, P. R., Hahne, M., Quiquerez, A. L., Schnuriger, V., Perrin, G., French, L., Vanmeir, E. G., Detribolet, N., Tschopp, J., and Dietrich, P. Y. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?. J. Clin. Invest., 99: 1173-1178, 1997.
13. Griffith, T. S., and Ferguson, T. A. The role of FasL-induced apoptosis in immune privilege. Immunol. Today, 18: 240-2244, 1997.
14. Wright, S. C., Zhong, J., Zheng, H., and Larrick, J. W. Inhibition of apoptosis as a mechanism of tumor promotion. FASEB J., 8: 654-660, 1994.
15. Tewari, M., and Dixit, V. M. Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product. J. Biol. Chem., 270: 3255-3260, 1995.
16. Kawanishi, M. Epstein-Barr virus BHRF1 protein protects intestine 407 epithelial cells from apoptosis induced by tumor necrosis factor alpha and anti-Fas antibody. J. Virol., 71: 3319-3322, 1997.
17. Sparano, J. A., Fisher, R. I., Weiss, G. R., Margolin, K., Aronson, F. R., Hawkins, M. J., Atkins, M. B., Dutcher, J. P., Gaynor, E. R., Boldt, D. H., Doroshow, J. H., Ernest, M. L., Sznol, M., and Mier, J. W. Phase II trials of high-dose interleukin-2 and lymphokine-activated killer-cells in advanced breast carcinoma and carcinoma of the lung, ovary and pancreas and other tumors. J. Immunother., 16: 216-223, 1994.
18. Henne-Bruns, D., Vogel, I., Lüttges, J., Klöppel, G. and Kremer, B. Ductal adenocarcinoma of the pancreas head: survival after regional versus extended lymphadenectomy. Hepato-Gastroenterol., in press, 1998.
19. Kalthoff, H., Roeder, C., Humburg, I., Thiele, H-G., Greten, H., and Schmiegel, W. Modulation of platelet-derived growth factor A- and B-chain/c-sis mRNA by tumor necrosis factor and other agents in adenocarcinoma cells. Oncogene, 6: 1015-1021, 1991.
20. Kalthoff, H., Schmiegel, W., Roeder, C., Kasche, D., Schmidt, A., Lauer, G., Thiele, H-G., Honold, G., Pantel, K., Riethmüller, G., Scherer, E., Maurer, J., Maacke, H., and Deppert, W. p53, and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene, 8: 289-298, 1993.
21. O'Connell, J., O'Sullivan, G. C., Collins, J. K., and Shanahan, F. The Fas counter-attack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med., 184: 1075-1082, 1996.
22. Sato, T., Irie, S., Kitada, S., and Reed, J. C. FAP-1: a protein tyrosine phosphatase that associates with Fas. Science (Washington DC), 268: 411-415, 1995.
23. Matzinger, P. The JAM test: a simple assay for DNA fragmentation and cell death. J. Immunol. Methods, 145: 185-192, 1991.
24. Alderson, M. R., Tough, T. W., Davis-Smith, T., Braddy, S., Falk, B., Schooley, K. A., Goodwin, R. G., Smith, C. A., Ramsdell, F., and Lynch, D. H. Fas ligand mediates activation-induced cell death in human T lymphocytes. J. Exp. Med., 181: 71-77, 1995.
25. Sanger, F., Nicklen, S., and Coulsen, A. R. DNA sequencing with chain-termination inhibitors. Proc. Natl. Acad. Sci. USA, 74: 5463-5467, 1977.
26. Tanaka, M., Suda, T., Takahashi, T., and Nagata, S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J., 14: 1129-1135, 1995.
27. Strand, S., Hofmann, W. J., Hug, H., Muller, M., Otto, G., Strand, D., Mariani, S. M., Stremmel, W., Krammer, P. H., and Galle, P. R. Lymphocyte apoptosis induced by CD95 (APO-1/Fas)ligand-expressing tumor cells - a mechanism of immune evasion?. Nat. Med., 2: 1361-1366, 1996.
28. Hayashi, H., Tatebe, S., Osaki, M., Goto, A., Suzuki, Y., and Ito, H. Expression of Fas antigen and its mediation of apoptosis in human gastric cancer cell lines. Jpn. J. Cancer Res., 88: 49-55, 1997.
29. Owen-Schaub, L. B., Radinsky, R., Kruzel, E., Berry, K., and Yonehara, S. Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res., 54: 1580-1586, 1994.
30. Yanagisawa, J., Takahashi, M., Kanki, H., Yano-Yanagisawa, H., Tazunoki, T., Sawa, E., Nishitoba, T., Kamishohara, M., Kobayashi, E., Kataoka, S., and Sato, T. The molecular interaction of Fas and FAP-1. J. Biol. Chem., 272: 8539-8545, 1997.
31. Zhang, B. X., Brunner, T., Carter, L., Dutton, R. W., Rogers, P., Bradley, L., Sato, T., Reed, J. C., Green, D., and Swain, S. L. Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J. Exp. Med., 185: 1837-1849, 1997.
32. McGahon, A. J., Nishioka, W. K., Martin, S. J., Mahboubi, A., Cotter, T. G., and Green, D. R. Regulation of the Fas apoptotic cell death pathway by Abl. J. Biol. Chem., 270: 22625-22631, 1995.
33. Furukawa, Y., Iwase, S., Terui, Y., Kikuchi, J., Sakai, T., Nakamura, M., Kitagawa, S., and Kitagawa, M. Transcriptional activation of the cdc2 gene is associated with Fas-induced apoptosis of human hematopoietic cells. J. Biol. Chem., 271: 28469-28477, 1996.
34. Mandal, M., Maggirwar, S. B., Sharma, N., Kaufmann, S. H., Sun, S. C., and Kumar, R. Bcl-2 prevents CD95 (Fas/APO-1)-induced degradation of lamin B and poly(ADP-ribose) polymerase and restores the NF-κB signaling pathway. J. Biol. Chem., 271: 30354-30359, 1996.
35. Mori, S., Murakami-Mori, K., Jewett, A., Nakamura, S., and Bonavida, B. Resistance of AIDS-associated Kaposi's sarcoma cells to Fas-mediated apoptosis. Cancer Res., 56: 1874-1879, 1996.
36. Shiraki, K., Tsuji, N., Shioda, T., Isselbacher, K. J., and Takahashi, H. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc. Natl. Acad. Sci. USA., 94: 6420-6425, 1997.
37. Hahne, M., Rimoldi, D., Schröter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J-C., and Tschopp, J. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science (Washington DC), 274: 1363-1366, 1996.
38. Niehans, G. A., Brunner, T., Prizelle, S. P., Liston, J. C., Salerno, C. T., Knapp, D. J., Green, D. R., and Kratzke, R. A. Human lung carcinomas express Fas ligand. Cancer Res., 57: 1007-1012, 1997.
39. Martinez-Lorenzo, M. J., Alava, M. A., Anel, A., Piniero, A., and Naval, J. Release of preformed Fas ligand in soluble form is the major factor for activation-induced death of Jurkat cells. Immunology, 89: 511-517, 1996.
40. French, L. E., and Tschopp, J. Constitutive Fas ligand expression in several non-lymphoid mouse tissues: implications for immune-protection and cell turnover. Behring Inst. Mitt., 97: 156-160, 1996.
41. Walker, P. R., Saas, P., and Dietrich, P-Y. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J. Immunol., 158: 4521-4524, 1997.
42. Seino, K., Kayagaki, N., Okumura, K., and Yagita, H. Antitumor effect of locally produced CD95 ligand. Nat. Med., 3: 165-170, 1997.